FDA Advises Pharma Companies On Social Media Issues

FDA issued two draft guidance for prescription drug manufacturers and distributors on dealing with social media platforms, concerning space limitations and correcting third-party misinformation. This responded to stakeholder requests for specific guidance and describes FDA’s current thinking on how manufacturers, packers, and distributors of prescription drugs and medical devices that choose to present benefit information should present both benefit and risk information within advertising and promotional labeling of their FDA-regulated products. Also see: Third-Party Misinformation Guidance.
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guida...